Preclinical toxicologic evaluation of bleomycin (NSC 125 066), a new antitumor antibiotic.
D000505:Alopecia / Q000139:chemically induced; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D001761:Bleomycin / Q000633:toxicity; D001797:Blood Protein Electrophoresis; D001798:Blood Proteins / Q000032:analysis; D001835:Body Weight; D001853:Bone Marrow / Q000473:pathology; D003872:Dermatitis / Q000139:chemically induced; D004285:Dogs; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006801:Humans; D007668:Kidney / Q000473:pathology; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008297:Male; D009393:Nephritis / Q000139:chemically induced; D009401:Nephrosis / Q000139:chemically induced; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D012220:Rhinitis / Q000139:chemically induced; D012712:Serum Globulins / Q000032:analysis; D012871:Skin Diseases / Q000139:chemically induced; D012883:Skin Ulcer / Q000139:chemically induced
D000903:Antibiotics, Antineoplastic; D001798:Blood Proteins; D012712:Serum Globulins; D001761:Bleomycin